| 周 芳,张英丽,朱 滔.晚期上皮性卵巢癌靶向治疗的研究进展[J].肿瘤学杂志,2021,27(1):15-21. |
| 晚期上皮性卵巢癌靶向治疗的研究进展 |
| Research Progress on Targeted Therapy of Advanced Epithelial Ovarian Cancer |
| 投稿时间：2020-07-21 |
| DOI：10.11735/j.issn.1671-170X.2021.01.B004 |
|
 |
| 中文关键词: 上皮性卵巢癌 靶向治疗 多腺苷二磷酸核糖聚合酶抑制剂 贝伐单抗 免疫检查点抑制剂 |
| 英文关键词:epithelial ovarian cancer targeted therapy poly ADP-ribose polymerase inhibitors bevacizumab immune checkpoint inhibitors |
| 基金项目:浙江省公益技术应用研究项目（LGF21H160008）；浙江省中医药重点研究研究项目（2021ZZ007）；浙江省教育厅一般科研项目（Y202044441） |
|
| 摘要点击次数: 1252 |
| 全文下载次数: 337 |
| 中文摘要: |
| 摘 要：上皮性卵巢癌目前治疗以手术联合化疗为主，但随着疾病的进展大多数患者不可避免会复发。近年来，靶向治疗在晚期上皮性卵巢癌的多线治疗中取得了突破性进展，多项研究提示以多腺苷二磷酸核糖聚合酶抑制剂和抗血管生成药物为主的靶向药物用于维持治疗能显著性延缓复发并改善患者的生存预后，此外，用于多线治疗后复发患者的单药治疗也初显疗效。虽然免疫检查点抑制剂单药治疗效果有限，但联合其他靶向或化疗药物可不同程度提高免疫活性。全文主要针对晚期上皮性卵巢癌靶向治疗和免疫治疗的研究进展进行综述。 |
| 英文摘要: |
| Abstract：Epithelial ovarian cancer(EOC) is a serious threat to the health of women. Currently，surgery combined with chemotherapy is the main treatment，however，as the disease progresses，it is inevitably to relapse for most patients. In recent years，targeted therapies have made breakthroughs in the multi-line treatment of advanced EOC. Several studies have shown that targeted drugs including poly ADP-ribose polymerase(PARP) inhibitors and anti-angiogenesis agents that used for maintenance therapy can significantly delay relapse and improve the survival of patients. In addition，single-agent therapy for patients with relapse after multi-line therapy also shows initial efficacy. Although the efficacy of immune checkpoint inhibitor monotherapy is limited，the combination with other targeted or chemotherapeutic drugs can improve immune activity. This article reviews the research progress of targeted therapy and immunotherapy for advanced EOC，and explores the most precise targeted therapy for patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |